Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Eur J Cancer. 2021 Aug 12;155:236–244. doi: 10.1016/j.ejca.2021.07.010

Table 3.

Dose modifications occurring in patients with GIST in the 150 mg IPDE population

Parameters, n (%) Ripretinib 150 mg QD period (n = 67) Ripretinib 150 mg IPDE period (n = 67)
Any TEAE leading to dose interruption 28 (41.8) 30 (44.8)
Any TEAE leading to dose reduction 4 (6.0) 6 (9.0)
Any TEAE leading to treatment discontinuation N/A 10 (14.9)

GIST, gastrointestinal stromal tumor; IPDE, intrapatient dose escalation; N/A, not applicable; QD, once daily; TEAE, treatment-emergent adverse event.